We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

pALTER®-MAX Vector

Q5761

Strong, Constitutive Expression of Cloned DNA Inserts in Mammalian Cells

  • Protein constitutively expressed from the human cytomegalovirus (CMV) immediate-early enhancer/promoter region in a variety of cell lines
  • SV40 late polyadenylation signal for efficient RNA processing
  • Restriction sites flanking the CMV enhancer (BglII and SgfI) and the CMV promoter (SgfI and I-PpoI) mean easy replacement by alternative regulatory regions

Size

Catalog number selected: Q5761

$ 331.00 Your price: Log In

Add to Helix
pALTER®-MAX Vector
20μg
$ 331.00
Your price: Log In

The pALTER®-MAX Vector is a 5,534bp plasmid that contains the human cytomegalovirus (CMV) immediate-early enhancer/promoter region for strong, constitutive expression of cloned DNA inserts in many mammalian cell types. A chimeric intron composed of the 5´-splice site from the β-globin intron and the 3´-splice site from an IgG intron also enhances expression levels. Synthesize RNA in vitro using the T7 and T3 RNA polymerase promoters that flank the multiple cloning site to generate sense or antisense strands. The pALTER®-MAX Vector as supplied is chloramphenicol-resistant and ampicillin-sensitive.

1471MA05_6A-W-01

pALTER®-MAX Vector  GenBank® Accession Number AF361302 and vector sequence text file.

Specifications

What's in the box?

Item Part # Size

pALTER®-MAX Vector

Q576A 1 x 20μg

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Resources

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom